Table 2.

Applications of SMART for testing some medicines.

Types	Result in ST Cross	Result in HB Cross	Range of Treated Doses and Remarks	Ref.
Atorvastatin	-	-	0–340 µM, all doses lack genotoxicity both ST and HB cross	[49]
Bupivacaine	-	-	10–500 µg/mL, inconclusive up to 500 µg/mL in ST cross and HB cross, inconclusive at 10 and 100 but lack genotoxicity at 250 and 500 µg/mL	[50]
Bupropion hydrochloride	+	+	0.937–7.5 mg/mL, inconclusive at 0.937 mg/mL and positive at 1.875–7.5 mg/mL in ST cross, whereby all of doses positive in HB cross	[51]
Doxorubicin	+	+	0.125 µM a dose show positive both ST and HB cross	[49]
Glimepiride	+	nd	10–100 µg, inconclusive at 10 µg and positive at 25–100 µg	[44]
Glipizide	+	nd	10–100 µg, inconclusive at up to 10 µg and positive at 25–100 µg	[44]
Levobupivacaine	-	+	100–1000 µg/mL, inconclusive up to 1000 µg/mL in ST cross; however, inconclusive up to 500 and positive at 1000 µg/mL in HB cross	[50]
Rosuvastatin	-	-	0–300 µM, all doses lack genotoxicity both ST and HB cross	[49]
Trazodone hydrochloride	+	+	0.937–7.5 mg/mL, all doses positive both ST and HB cross	[51]

nd—not determined, (-)—negative, and (+)—positive.